Effect of different chemically modified oligodeoxynucleotides on immune stimulation

Biochemical Pharmacology

Volumn 51, Issue 2, 1996, Pages 173-182

  Zhao, Qiuyan ^a   Temsamani, Jamal ^a   Iadarola, Patricia L ^a   Jiang, Zhiwei ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

cell proliferation; chemical modification; immune stimulation; oligonucleotide

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DEPLETION; IMMUNOSTIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; T LYMPHOCYTE;

EID: 0030071007     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02177-9     Document Type: Article

References (27)

1. Agrawal S and Iyer RP, Modified oligonucleotides as therapeutic and diagnostic agents. Curr Opin Biotechnol 6: 12-19, 1995.
2. Agrawal S, Antisense oligonucleotides as antiviral agents. Trends Biotechol 10: 152-158, 1992.
3. Crooke S and Lebleu B (Eds.), Antisense Research and Applications. CRC Press, Boca Raton, FL, 1993.
4. Stein CA and Cheng Y-C, Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261: 1004-1012, 1993.
5. Agrawal S, Temsamani J and Tang JY, Self-stabilized oligonucleotides as novel antisense agents. In: Delivery Strategies for Antisense Oliganucleotide Therapeutics (Ed. Akhtar S), pp. 105-122. CRC Press, Boca Raton, FL, 1995.
6. Bayever E, Iversen PL, Bishop MR, Sharp GJ, Tewary HK, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger A, Zon G and Atmitage JO, Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial. Antisense Res Dev 3: 383-390, 1993.
7. 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharmacol Ther 56: 641-646, 1994.
8. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S and Diasio RB, Human pharmacokinetics of an anti-HIV antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected individuals. Clin Pharmocol Ther 58: 44-53, 1995.
9. Stollar BD, Immunochemical analyses of nucleic acids. Prog Nucleic Acid Res Mol Biol 42: 39-77, 1992.
10. Gilkeson GS, Grudier JP, Karounos DG and Pisetsky DS, Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. J Immunol 142: 1482-1486, 1989.
11. Frappier L, Price GB, Martin RG and Zannis-Hadjopoulos M, Monoclonal antibodies to cruciform DNA structures. J Mol Biol 193: 751-758, 1987.
12. Beaucage S, Oligodeoxynucleotide synthesis: Phosphoramidite approach. In: Protocols for Oligonudeotides and Analogs: Synthesis and Properties (Ed. Agrawal S), pp. 33-62. Humana Press, Totowa, NJ, 1993.
13. Padmapriya A, Tang JY and Agrawal S, Large scale synthesis, purification and analysis of oligonucleotide phosphorothioates. Antisense Res Dev 4: 185-199, 1994.
14. Branda RF, Moore AL, Mathews L, McCormack JJ and Zon G, Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol 45: 2037-2043, 1993.
15. Kuramoto E, Yano O, Kimura Y, Baba M, Makino T, Yamamoto S, Yamamoto T, Kataoka T and Tokonaga T, Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res 83: 1128-1131, 1992.
16. Agrawal S and Tang JY, GEM 91 - An antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev 2: 261-266, 1992.
17. Agrawal S and Lisziewicz J, Potential for HIV-1 treatment with antisense oligonucleotides. J Biotechnol Healthcare 1: 167-182, 1994.
18. Tang JY, Temsamani J and Agrawal S, Self-stabilized antisense oligodeoxynucleotide phosphorothioates. Nucleic Acids Res 20: 2729-2735, 1993.
19. Zhang R, Diasio RB, Lu Z, Kiu T, Jiang Z, Galbraith W and Agrawal S, Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49: 929-939, 1995.
20. Zhang R, Lu Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D and Agrawal S, In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem Pharmocol 50: 545-556, 1995.
21. Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Shimada T, Stein CA, Mitsuya H, Wong-Stall F, Cohen JS and Broder S, Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci USA 86: 4244-4248, 1989.
22. McIntyre K, Lombardo-Gillooly K, Perez J, Kunsch C, Sarmiento U, Larigan D, Landreth D and Narayanan R, A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-κB p65 causes sequence-specific immune stimulation. Antisense Res Dev 3: 309-322, 1993.
23. Krieg AM, Yi AE, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA and Klinman D, CpG motifs in bacterial DNA trigger B-cell activation. Nature 374: 546-549, 1995.
24. Messina J, Gilkeson G and Pisetsky D, The influence of DNA structure on the in vivo stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol 147: 148-157, 1993.
25. Pisetsky D and Reich C, Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci 54: 101-107, 1994.
26. Temsamani J, Kubert M, Tang JY, Padmapriya A and Agrawal S, Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res Dev 4: 35-42, 1994.
27. Zhao Q, Matson S, Herrera C, Fisher E, Yu H and Krieg A, Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3: 53-66, 1993.